Sunday, June 14, 2026

Patent directory · USPTO A61K / A61P

Browse patents

Browse 30,257 pharma-relevant patents (US A61K/A61P) linked to tracked companies, drugs, and pipeline programs.

Patents indexed 30,257
Companies 1,769
Drugs linked 4,797

Quick answer

NovaPharmaNews indexes 30,257 US pharmaceutical patents from USPTO PatentsView (CPC A61K/A61P), cross-linked to company assignees, drug INN profiles, and pipeline programs. Search by patent number, applicant, title, or CPC code — or use facet hubs for expiring patents, assignees, and therapeutic areas.

Patent results

Page 140 of 1,261
  1. CA 3256289

    MÉTHODES PERMETTANT DE FAVORISER LA CROISSANCE DE RATTRAPAGE SAINE

    ABBOTT LAB [US] · Granted Feb 1, 2024 · Expires Jan 27, 2044

    granted
  2. CA 3259391

    POLYTHÉRAPIE ANTI-GARP-TGF-β1/PD-1

    ABBVIE BIOTHERAPEUTICS INC [US] · Granted Feb 1, 2024 · Expires Jan 27, 2044

    granted
  3. CA 3259243

    POLYTHÉRAPIE ANTICANCÉREUSE COMPRENANT UN INHIBITEUR DE BCL-2

    RYVU THERAPEUTICS S A [PL] · Granted Feb 1, 2024 · Expires Jan 27, 2044

    granted
  4. CA 3263005

    POLYPEPTIDES SE LIANT À UN ÉPITOPE SPÉCIFIQUE DU RÉCEPTEUR FC NÉONATAL

    SANOFI SA [FR] · Granted Feb 1, 2024 · Expires Jan 27, 2044

    granted
  5. CA 3259252

    POLYTHÉRAPIE ANTICANCÉREUSE COMPRENANT UN INHIBITEUR DE FLT3

    RYVU THERAPEUTICS S A [PL] · Granted Feb 1, 2024 · Expires Jan 27, 2044

    granted
  6. US 11883408

    Reboxetine to treat narcolepsy

    AXSOME THERAPEUTICS, INC. · Granted Jan 30, 2024 · Expires Jan 25, 2044

    granted
  7. US 11884707

    Compositions for detection, inhibition and imaging of indoleamine 2, 3-dioxygenase 1 (IDO1) and methods of making and using same

    REGENERON PHARMACEUTICALS, INC. · Granted Jan 30, 2024 · Expires Jan 25, 2044

    granted
  8. US 11884731

    Vedolizumab for the treatment of fistulizing Crohn's disease

    Takeda Pharmaceutical Company Limited · Granted Jan 30, 2024 · Expires Jan 25, 2044

    granted
  9. US 11884736

    Antibodies which bind to glucagon-like peptide 1 receptor (GLP1R)

    REGENERON PHARMACEUTICALS, INC. · Granted Jan 30, 2024 · Expires Jan 25, 2044

    granted
  10. US 11884944

    Fusion proteins comprising sulfoglucosamine sulfohydrolase enzymes and methods thereof

    DENALI THERAPEUTICS INC. · Granted Jan 30, 2024 · Expires Jan 25, 2044

    granted
  11. US 11884919

    Lipid formulated compositions and methods for inhibiting expression of serum amyloid a gene

    Alnylam Pharmaceuticals, Inc. · Granted Jan 30, 2024 · Expires Jan 25, 2044

    granted
  12. US 11883528

    Compositions and methods for treating pulmonary edema or lung inflammation

    Regents of the University of Minnesota · Granted Jan 30, 2024 · Expires Jan 25, 2044

    granted
  13. US 11883468

    Compositions and methods to suppress tumor growth in bone, prevent cachectic muscle loss, and preserve skeletal integrity

    United States Government as represented by the Department of Veterans Affairs · Granted Jan 30, 2024 · Expires Jan 25, 2044

    granted
  14. US 11883420

    Sting agonists for treating bladder cancer and solid tumors

    VENENUM BIODESIGN, LLC · Granted Jan 30, 2024 · Expires Jan 25, 2044

    granted
  15. US 11883381

    ASH1L inhibitors and methods of treatment therewith

    THE REGENTS OF THE UNIVERSITY OF MICHIGAN · Granted Jan 30, 2024 · Expires Jan 25, 2044

    granted
  16. US 11883386

    Prolyl hydroxylase inhibitors and methods of use

    Akebia Therapeutics, Inc. · Granted Jan 30, 2024 · Expires Jan 25, 2044

    granted
  17. US 11883423

    Nucleobase analogue derivatives and their applications

    The Board of Regents of the University of Texas System · Granted Jan 30, 2024 · Expires Jan 25, 2044

    granted
  18. US 11883223

    Hepatic inflammation analysis with dynamic PET

    The Regents of the University of California · Granted Jan 30, 2024 · Expires Jan 25, 2044

    granted
  19. US 11884930

    Method of inactivating a glucocorticoid receptor gene in an isolated cell

    Sangamo Biosciences, Inc. · Granted Jan 30, 2024 · Expires Jan 25, 2044

    granted
  20. US 11885806

    Method for depleting malignant T-cells

    AUTOLUS LIMITED · Granted Jan 30, 2024 · Expires Jan 25, 2044

    granted
  21. US 11885817

    Biomarkers and methods for detection of seizures and epilepsy

    Cognizance Biomarkers, LLC · Granted Jan 30, 2024 · Expires Jan 25, 2044

    granted
  22. US 11884715

    Activin receptor type IIB variants and methods of use thereof

    Keros Therapeutics, Inc. · Granted Jan 30, 2024 · Expires Jan 25, 2044

    granted
  23. US 11883432

    Chimeric antigen receptor system with adaptable receptor specificity

    Century Therapeutics, Inc. · Granted Jan 30, 2024 · Expires Jan 25, 2044

    granted
  24. US 11883441

    Compositions and methods for inhibiting seizures

    The Regents of the University of California · Granted Jan 30, 2024 · Expires Jan 25, 2044

    granted

Frequently asked questions

What patents are included in this directory?

We index 30,257 published US pharma-relevant patents filtered to CPC classes A61K and A61P, with assignee links to our company directory where a match exists.

How do I search for a patent?

Use the search box to match patent number, title, applicant name, or CPC classification (e.g. A61K). For cross-entity queries spanning news and drugs, use the global search.

How is this different from the patent intelligence dashboard?

The dashboard at /patents highlights expirations, recent grants, and assignee rankings. Browse is the full paginated directory with search — best for looking up a specific filing or applicant portfolio slice.